Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Autolus Therapeutics plc (AUTL) is a Biotechnology company based in GB with a market capitalization of $389.9M. Revenue grew 646.7% year-over-year and free cash flow was negative at -$302.7M. This page tracks AUTL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
GB · 647 employees · IPO Jun 22, 2018
Valuation
Valuation & price
$1.69as of May 26, 2026· -33.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.19
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$389.9M
Market cap
646.7%
Revenue growth (YoY)
-27.8%
Gross margin
-$302.7M
Free cash flow (USD)
$50.9M
Net debt
4.3%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 14, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 29, 2026Filing
Annual General Meeting Results
- 8-K eventJun 9, 2026Filing
Annual Report Filed
- 8-K eventMay 14, 2026Filing
Earnings Release
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventApr 29, 2026Filing
Workforce Reduction
- 8-K eventApr 16, 2026Filing
Accounting Firm Change
- FinancingApr 13, 2026Filing
Securities Registration
- FinancingApr 13, 2026Filing
Securities Registration
- 8-K eventApr 8, 2026Filing
Investor Event Announcement
Questions
Frequently asked questions
What is Autolus Therapeutics plc's market cap?
Autolus Therapeutics plc (AUTL) has a market capitalization of $389.9M.
What is AUTL's P/E ratio?
A meaningful P/E ratio is not available for AUTL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is AUTL's price-to-book (P/B) ratio?
AUTL trades at 2.19 times book value per share.
Are insiders buying AUTL stock?
SEC Form 4 filings show no open-market insider buys at Autolus Therapeutics plc in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.